Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
James J. Hsieh(Memorial Sloan Kettering Cancer Center), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center), Nancy Bouvier(University of California, San Francisco), Patrizia Pinciroli(Memorial Sloan Kettering Cancer Center), Michael F. Berger(Memorial Sloan Kettering Cancer Center), Helen Won(Unknown), Nicholas D. Socci, Agnès Viale(Genomics (United Kingdom)), Michael Chevinsky(Barnes-Jewish Hospital), Jennifer J. Knox(National Cancer Center), Daoqi You(Memorial Sloan Kettering Cancer Center), Maurizio Voi(Curis (United States)), Kety Huberman, Patricia I. Wang(Memorial Sloan Kettering Cancer Center), Nils Weinhold(Memorial Sloan Kettering Cancer Center), Umesh Bhanot(Memorial Sloan Kettering Cancer Center), A. Ari Hakimi(Penn State Milton S. Hershey Medical Center), Martin H. Voss(Memorial Sloan Kettering Cancer Center), William Lee(Drexel University), Parul Patel(Novartis (United States)), Emily H. Cheng(University of Wisconsin–Madison), David Chen(Novartis (United States)), Ying‐Bei Chen(Memorial Sloan Kettering Cancer Center), Mahtab Marker(Novartis (United States)), S. Duygu Selçuklu(Memorial Sloan Kettering Cancer Center)
Cited by 204
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
|Cell Death and Differentiation|2018|6.6k
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.6k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k